세계의 카나비노이드(Cannabinoids) 시장 보고서(2025년)
Cannabinoids Global Market Report 2025
상품코드 : 1821619
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

카나비노이드 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 20.7%를 나타내 998억 2,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 보다 광범위한 합법화와 비범죄화, 조사의 진보, 다양한 제품의 제공, 국제시장 확대, 공중위생의식 향상에의 대처에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 수용의 확대와 비인지화, 제품 제공의 다양화, 전달방법의 혁신, 품질과 안전성의 기준, 사회적 공정성과 포괄성의 대처 등이 있습니다.

향후 5년간의 성장률 20.7%라고 하는 예측은 이 시장의 전회 예측으로부터 0.4%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 포르투갈과 이스라엘에서 수입되는 식품의약국(FDA) 승인 대마초 유래 의약품 및 표준화된 CBD 제제의 비용을 증가시키고 대체 통증 치료 옵션을 줄일 수 있으므로 미국의 통증 관리를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

만성 질환의 유병률 증가는 카나비노이드 시장 성장을 가속할 것으로 예측됩니다. 만성 질환은 일반적으로 지속적인 의료가 필요한 장기간의 질병입니다. 무작위 비교 시험의 체계적인 검토는 훈제 대마초, 대마초 기반 약물의 점막 추출물, 나비론, 드로나비놀 및 신규 THC 유사체를 비롯한 카나비노이드의 비암성 만성 통증 관리에 대한 효능을 조사했습니다. 예를 들어 2023년 9월 스위스에 본부를 두는 유엔기구인 세계보건기구(WHO)는 세계 사망자 수의 74%에 해당하는 4,100만명이 매년 비감염성 질환(NCDs) 또는 만성 질환으로 사망하고 있다고 보고했습니다. 그 결과 만성질환의 만연이 카나비노이드 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Cannabinoids are specific chemical compounds found in marijuana that exert effects on the immune and central nervous systems similar to certain drugs. These compounds are utilized to alleviate side effects or symptoms associated with chronic diseases, particularly in the context of cancer treatment.

The primary types of cannabinoid products include cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol, and other variants. Cannabidiol is employed in the treatment of conditions such as seizures, anxiety, insomnia, chronic pain, and tobacco addiction. It is a chemical component derived from the cannabis sativa plant or hemp. The distribution channels for cannabinoids encompass hospital pharmacies, retail pharmacies, and online stores. Applications for cannabinoids span medical, recreational, and industrial hemp uses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cannabinoids protection market research report is one of a series of new reports from The Business Research Company that provides cannabinoids market statistics, including cannabinoids industry global market size, regional shares, competitors with a cannabinoids market share, detailed cannabinoids market segments, market trends and opportunities, and any further data you may need to thrive in the cannabinoids industry. This cannabinoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cannabinoids market size has grown rapidly in recent years. It will grow from $39.45 billion in 2024 to $47.03 billion in 2025 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to medical cannabis legalization, increasing acceptance of cannabis, research and development, regulatory changes, growing awareness of cannabinoid benefits, investments in cannabis industry, consumer trends toward natural products.

The cannabinoids market size is expected to see exponential growth in the next few years. It will grow to $99.82 billion in 2029 at a compound annual growth rate (CAGR) of 20.7%. The growth in the forecast period can be attributed to wider legalization and decriminalization, research advancements, diverse product offerings, international market expansion, public health awareness initiatives. Major trends in the forecast period include increasing acceptance and destigmatization, diversification of product offerings, innovation in delivery methods, quality and safety standards, social equity and inclusivity initiatives.

The forecast of 20.7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. pain management by increasing costs for Food and Drug Administration(FDA)-approved cannabis-derived medications and standardized CBD formulations imported from Portugal and Israel, potentially reducing alternative pain therapy options. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic diseases is expected to drive the growth of the cannabinoid market. Chronic diseases are long-lasting conditions that typically require ongoing medical care. A systematic review of randomized controlled trials examined the effectiveness of cannabinoids, including smoked marijuana, oromucosal extracts of cannabis-based medications, nabilone, dronabinol, and a new THC analogue, in managing chronic noncancer pain. For example, in September 2023, the World Health Organization (WHO), a Switzerland-based United Nations agency, reported that 41 million deaths, or 74% of global deaths, were caused by non-communicable diseases (NCDs) or chronic diseases annually. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the cannabinoid market.

The rising prevalence of cancer is expected to drive the growth of the cannabinoid market. Cancer is a condition in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cannabinoids are increasingly used to support cancer patients by managing symptoms such as neuropathy, nausea, pain, vomiting, appetite loss, and weight loss. Additionally, cannabinoids can influence cancer progression by stimulating autophagy and affecting signaling pathways that lead to apoptosis (cell death). For example, in January 2022, the American Cancer Society reported an estimated 1,918,030 new cancer cases and 609,360 cancer-related deaths in the United States. Among these, around 350 people are expected to die each day from lung cancer, which remains the leading cause of cancer-related deaths. As a result, the increasing prevalence of cancer is contributing to the growth of the cannabinoid market.

Major companies in the cannabinoids market are strategically focusing on introducing advanced cannabis-based cosmetic solutions to gain a competitive edge. Cannabis-based cosmetic solutions, like CBG and CBD rescue cream, are formulated with cannabis derivatives to offer skin moisturizing, anti-aging, and anti-inflammatory effects. For instance, in November 2022, British Cannabis, a UK-based producer, introduced the Synergy CBG and CBD Rescue Cream, the first cannabis cosmetic in the UK to undergo clinical trials. This innovative product reflects a commitment to creating comprehensive skincare solutions in the cannabinoid market.

Major companies in the cannabinoids market are focusing on developing innovative solutions like fast-acting cannabinoids to enhance the efficacy and speed of therapeutic effects. Fast-acting cannabinoids refer to formulations that deliver quicker relief compared to traditional methods. For example, in August 2024, Rare Cannabinoid, a US-based health and wellness company, launched Fast-Acting Nano THC + CBC Mood Mints. These mints provide rapid effects, allowing users to feel the benefits of delta-9-THC and cannabichromene (CBC) within 15 to 30 minutes, compared to the usual 30 to 90 minutes for traditional edibles. Using advanced nanotechnology, the mints offer customizable dosing options, ideal for microdosing and personalized use.

In January 2022, Dermapharm Holding SE, a Germany-based pharmaceutical company, acquired C3 Group for an undisclosed amount. The acquisition aimed to strengthen Dermapharm Holding's position in the growing cannabis market by enhancing its cannabinoid production capabilities, expanding its distribution channels across Europe, and deepening its expertise in therapeutic solutions for serious medical conditions. This move comes as regulatory changes increasingly favor the acceptance of medical cannabis. C3 Group, a Poland-based company, specializes in cannabinoid compounds, contributing to Dermapharm's strategic push into this emerging sector.

Major companies operating in the cannabinoids market are The Supreme Cannabis Company Inc., Elixinol Global Limited, GW Pharmaceuticals PLC., Tilray Inc., Aurora Cannabis Inc., Innovative Ind Props, Curaleaf Holdings Inc., Green Thumb Industries, Verano Holdings, Trulieve Cannabis Corp., Cresco Labs Inc., Cronos Group, TerrAscend Corp., Canopy Growth Corp., Sundial Growers Inc., Decibel Cannabis Company, Auxly Cannabis Group, Red White & Bloom Brands, BZAM Ltd, Delta 9 Cannabis Inc., Mylan N.V., Westleaf Cannabis Inc., GrowGeneration, The Scotts Miracle-Gro Company, Jazz Pharmaceuticals PLC, Aphria Inc., Organigram Inc., Alkem labs, MediPharm Labs Corp., The Valens GroWorks Inc.

North America was the largest region in the cannabinoids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabinoids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cannabinoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cannabinoids market consists of sales of cannabidiolic acid, flowers/buds and concentrates. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cannabinoids Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cannabinoids market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cannabinoids ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cannabinoids market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cannabinoids Market Characteristics

3. Cannabinoids Market Trends And Strategies

4. Cannabinoids Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cannabinoids Growth Analysis And Strategic Analysis Framework

6. Cannabinoids Market Segmentation

7. Cannabinoids Market Regional And Country Analysis

8. Asia-Pacific Cannabinoids Market

9. China Cannabinoids Market

10. India Cannabinoids Market

11. Japan Cannabinoids Market

12. Australia Cannabinoids Market

13. Indonesia Cannabinoids Market

14. South Korea Cannabinoids Market

15. Western Europe Cannabinoids Market

16. UK Cannabinoids Market

17. Germany Cannabinoids Market

18. France Cannabinoids Market

19. Italy Cannabinoids Market

20. Spain Cannabinoids Market

21. Eastern Europe Cannabinoids Market

22. Russia Cannabinoids Market

23. North America Cannabinoids Market

24. USA Cannabinoids Market

25. Canada Cannabinoids Market

26. South America Cannabinoids Market

27. Brazil Cannabinoids Market

28. Middle East Cannabinoids Market

29. Africa Cannabinoids Market

30. Cannabinoids Market Competitive Landscape And Company Profiles

31. Cannabinoids Market Other Major And Innovative Companies

32. Global Cannabinoids Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cannabinoids Market

34. Recent Developments In The Cannabinoids Market

35. Cannabinoids Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기